United States Patent 8,246,979: What the Claims Actually Cover (and What They Block)
US Drug Patent 8,246,979 is directed to a rotigotine transdermal delivery system (TDS) built around a self-adhesive, semi-permeable polymer matrix containing rotigotine in free base form housed in microreservoirs. The claim set draws a tight separation between free base rotigotine (permeates) and the protonated form (substantially blocked) at the matrix level, then tightens formulation and morphology via microreservoir size, loading, count, and inhibitor/adhesive composition constraints.
Core claim 1: the operating definition of scope
Claim 1 defines a TDS with five mutually reinforcing elements:
-
Architecture
- A transdermal delivery system with:
- Backing layer (explicitly “inert to the components of the matrix”).
- Self-adhesive matrix containing rotigotine.
-
Form of active
- Rotigotine is in free base form.
- The free base is isolated prior to incorporation into the matrix.
- The system distinguishes between:
- Rotigotine free base (permeable).
- Protonated rotigotine (substantially impermeable).
-
Internal storage geometry
- A multitude of microreservoirs within the matrix.
- Microreservoirs contain rotigotine free base.
-
Selective permeability behavior
- The matrix is permeable to free base rotigotine.
- The matrix is substantially impermeable to the protonated form of rotigotine.
-
Microreservoir size constraint vs matrix thickness
- “All the microreservoirs have a maximum diameter that is less than the thickness of the matrix.”
This claim set is not a generic rotigotine patch claim. It is a free-base selective permeability microreservoir system with a specific morphology relationship (reservoir diameter relative to matrix thickness) and a process/form requirement (free base isolated prior to incorporation).
What Each Dependent Claim Adds to the Scope
Claim 2: microreservoir mean size band
- Microreservoirs have a mean diameter of 0.5 to 20 µm.
This narrows the reservoir size distribution and can limit infringement to systems that land in that statistical band.
Claim 3: interface salt-absorption limitation
- Matrix is free of particles that can absorb salts of rotigotine at the TDS/skin interface.
This is an additional anti-salt interface constraint. It targets formulations that include salt-absorbing excipients at the interface region (which would undermine the claim’s “substantially impermeable to protonated form” behavior).
Claim 4-6: silicone PSA composition and tack level
- Claim 4: matrix comprises a silicone pressure sensitive adhesive.
- Claim 5: matrix comprises two or more silicone pressure sensitive adhesives as main adhesive components.
- Claim 6: the two or more silicone PSAs comprise:
- A high tack silicone PSA: polysiloxane + resin.
- A medium tack silicone PSA: polysiloxane + resin.
This set hard-wires adhesive chemistry into the protected embodiments and limits coverage against non-silicone adhesives or silicone systems outside the “high tack + medium tack” structural PSA blend concept.
Claim 7: medical use method
- Method for treating rotigotine-responsive disease by applying the TDS of claim 1 to skin.
This is a classic use claim that ties coverage to practicing the claimed device.
Claim 8-9: crystallization inhibitor
- Claim 8: microreservoirs additionally contain at least one crystallization inhibitor selected from:
- soluble polyvinylpyrrolidone (PVP),
- copolymer of PVP and vinyl acetate,
- polyethylene glycol,
- polypropylene glycol,
- glycerol,
- fatty acid ester of glycerol,
- copolymer of ethylene and vinyl acetate.
- Claim 9: crystallization inhibitor comprises soluble PVP.
This portion narrows embodiments where the system includes specific anti-crystallization excipients in the reservoirs.
Claim 10-11: microreservoir density per cm²
Two dependent claims specify different density ranges:
- Claim 10: 103 to 109 microreservoirs per cm².
- Claim 11: 106 to 109 microreservoirs per cm².
These numerical windows are enforceability anchors. Any product with reservoir density outside these bands avoids those dependent limitations, unless independent claim 1 still reads.
Claim 12-13: maximum diameter constraints
- Claim 12: maximum diameter not greater than 35 µm.
- Claim 13: maximum diameter 2.5 to 30 µm.
These act as alternative tightening gates. Together with claim 1 (max diameter < matrix thickness), they bound both absolute and relative geometries.
Claims 14-16: salt content threshold for rotigotine salts
Dependent claims require that any rotigotine salt present (if any) remains low:
- Claim 14: < 5% w/w of self-adhesive matrix.
- Claim 15: < 2% w/w.
- Claim 16: < 1% w/w.
These thresholds constrain “free base” reality. A patch with meaningful salt formation risks non-infringement for these dependent claims.
Claim 17: free base isolated in solid form prior to incorporation
- Free base rotigotine isolated in solid form prior to incorporation.
This strengthens the process/form element already stated in claim 1 (“isolated prior to its incorporation”) by specifying the isolation as solid.
Claim 18: reservoir mean diameter relative to matrix thickness
- Mean diameter is between 1-40% of matrix thickness.
This claim creates a second morphology linkage. It can be used to argue infringement or design-around based on thickness and reservoir statistics.
Infringement Core: The Must-Haves and the Likely Design-Around Routes
The “must-hit” elements of claim 1
To read on claim 1, an accused TDS must match all of the following conceptually:
- It is a rotigotine TDS with a backing layer and self-adhesive matrix.
- Rotigotine is in free base form, and the free base is isolated prior to incorporation.
- The matrix includes microreservoirs and those reservoirs contain rotigotine free base.
- The matrix is:
- permeable to free base,
- substantially impermeable to the protonated form.
- Reservoir max diameter < matrix thickness (for all microreservoirs).
- The backing layer is inert to matrix components.
Design-around logic (claim-structure driven, not speculative product-by-product)
The claim language points to specific ways a competitor can reduce risk:
-
Break the free-base/protonated selectivity
- If the matrix allows protonated rotigotine to permeate materially, claim 1’s selective permeability feature weakens.
-
Avoid microreservoir architecture
- Claim 1 requires “multitude of microreservoirs” containing free base.
- A homogeneous matrix without microreservoirs is structurally outside the claim.
-
Change the reservoir-matrix thickness relationship
- Claim 1 is explicit: maximum reservoir diameter is less than matrix thickness.
- Systems with different reservoir sizing rules that violate this relationship can avoid claim 1.
-
Alter adhesive system composition
- Claims 4-6 narrow to silicone PSAs (and to blends of high-tack and medium-tack silicone PSAs).
- A system using different adhesive chemistries can evade dependent claims, though it may still face independent claim 1 if it otherwise meets the base architecture.
-
Control reservoir density or size distribution
- Claims 2, 10, 11, 12, 13, and 18 narrow dependent scope with quantitative geometry and density.
- A product outside these dependent ranges may still potentially land on claim 1, but it reduces the set of dependent claim hooks.
-
Keep salt content above the dependent thresholds
- Claims 14-16 are numeric caps on rotigotine salt presence.
- A system that allows higher salt formation can avoid those dependents.
-
Do not isolate free base in the required manner
- Claim 17 specifies solid-form isolation prior to incorporation.
- If a competitor does not practice the isolation step described, it can contest process/form limitations, though the claim 1 “isolated prior to incorporation” element remains central.
Patent Landscape: How 8,246,979 Likely Sits in the Rotigotine Patch Space
US 8,246,979 should be analyzed as a formulation architecture patent (free base + microreservoir matrix + selective permeability) with strong “device-in-use” hooks (claim 7).
What this patent likely covers relative to adjacent rotigotine TDS technologies
This patent is characterized by three differentiators that commonly appear as the patent battleground in transdermal delivery:
- Drug form selection: rotigotine free base rather than salt.
- Salt/protonation control mechanism: matrix permeability is tailored to treat free base and protonated species differently.
- Morphology: microreservoirs and their geometry versus matrix thickness.
In a landscape review, these differentiators typically define claim scope boundaries against:
- rotigotine patch patents focused on adhesive layers without microreservoir reservoirs,
- patents focused on chemical penetration enhancers rather than selective permeability to specific ionic forms,
- patents focused on general nanocarrier drug loading without microreservoir morphology,
- patents focused on different active forms or different permeability targets.
Enforcement posture implied by the claim set
- Independent claim 1 is broad enough to read on any rotigotine TDS that uses:
- microreservoirs containing free base rotigotine,
- with selective permeability that blocks protonated species,
- with reservoir diameter constrained relative to matrix thickness,
- and uses an inert backing.
- Dependent claims then allow the patentee to pursue narrower portfolios:
- reservoir size bands,
- reservoir density bands,
- specific crystallization inhibitors,
- specific silicone PSA blends,
- and low salt-content embodiments.
That structure is consistent with a litigation strategy where claim 1 supports a broad theory and dependent claims offer fallback positions tied to measurable technical parameters.
Claim-to-Design Parameter Matrix (Technical Variables That Matter in Freedom-to-Operate)
| Patent element |
Claim(s) |
Practical measurement target |
| Rotigotine free base isolated before incorporation |
1, 17 |
Free-base isolation step and form (solid prior) |
| Microreservoir architecture present |
1 |
Presence and morphology of microreservoirs |
| Microreservoir contains free base |
1 |
Content identification within microreservoirs |
| Matrix permeable to free base |
1 |
Permeation of free base through matrix |
| Matrix substantially impermeable to protonated rotigotine |
1 |
Permeation or transport of protonated form |
| Backing layer inert to matrix components |
1 |
Chemical inertness / compatibility specification |
| Microreservoir max diameter < matrix thickness |
1 |
Ratio of reservoir max diameter vs matrix thickness |
| Mean diameter range |
2 |
0.5 to 20 µm (mean) |
| Max diameter upper bound |
12 |
≤ 35 µm |
| Max diameter range |
13 |
2.5 to 30 µm |
| Mean diameter as % of thickness |
18 |
1-40% of thickness |
| Microreservoir density |
10, 11 |
103 to 109 per cm²; or 106 to 109 per cm² |
| Salt-free/interfacial salt absorption exclusion |
3 |
No particles absorbing rotigotine salts at TDS/skin interface |
| Silicone PSA presence |
4 |
Silicone PSA in matrix |
| Two silicone PSAs main components |
5 |
Blend-based PSA architecture |
| High tack + medium tack silicone PSA composition |
6 |
Polysiloxane + resin high tack and polysiloxane + resin medium tack |
| Crystallization inhibitor in microreservoirs |
8, 9 |
PVP and/or specified inhibitors |
| Rotigotine salt content cap |
14-16 |
<5%, <2%, <1% w/w of matrix |
Key Takeaways
- US 8,246,979 protects a rotigotine free-base microreservoir transdermal system with a self-adhesive polymer matrix that is permeable to free base but substantially impermeable to protonated rotigotine, plus a microreservoir size constraint tied to matrix thickness (claim 1).
- The claim set is designed to be enforceable through measurable physical parameters (reservoir mean/max diameter, density per cm², reservoir-to-thickness ratio) and chemical/functional differentiation (free base isolation, selective permeability, and low salt content).
- Dependent claims then add quantitative and compositional restrictions (silicone PSA blend design, PVP-based crystallization inhibition, specific microreservoir density bands, and salt thresholds), enabling narrower fallback positions if claim 1 is contested.
FAQs
1) Does claim 1 require rotigotine to be a free base instead of a salt?
Yes. Claim 1 requires rotigotine in free base form, with the free base isolated prior to incorporation.
2) What structural element makes this patent different from generic rotigotine patches?
Claim 1 requires a self-adhesive matrix containing microreservoirs where microreservoirs contain rotigotine free base, plus a selective permeability behavior versus protonated rotigotine.
3) Are microreservoir size limits only in dependent claims?
No. Claim 1 includes a critical morphology condition: microreservoir maximum diameter is less than matrix thickness. Dependent claims add further numeric caps and ranges.
4) Can a product infringe dependent claims without infringing claim 1?
In practice, dependent claims sit “inside” claim 1. If claim 1 is not met, dependent claims cannot be met as a matter of claim dependency.
5) What are the key measurable variables to screen for infringement risk?
Microreservoir presence, free base isolation and loading form, selective permeability to free base vs protonated form, reservoir density, reservoir diameter statistics, and any salt content at specified thresholds.
References
[1] United States Patent No. 8,246,979.
